Barrington analyst Michael Petusky maintained a Buy rating on SurModics (NASDAQ: SRDX) today and set a price target of $73. The company’s shares opened today at $66, close to its 52-week high of $67.67.
Petusky noted:
“We are now modeling adjusted FY/18 adjusted EPS of $0.43 and revenue of $80.8 million.”
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 16.3% and a 64.4% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SurModics with a $74 average price target, representing a 12.1% upside. In a report released yesterday, Needham also reiterated a Buy rating on the stock with a $74 price target.
.
See today’s analyst top recommended stocks >>
SurModics’ market cap is currently $865.7M and has a P/E ratio of 933.57. The company has a Price to Book ratio of 7.64.
Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2018, Jose Bedoya, a Director at SRDX sold 11,450 shares for a total of $551,547.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to the healthcare industry. It operates through the Medical Device and In Vitro Diagnostics segments.
